Elite Pharmaceuticals, Inc.
ELTP
$0.26
$0.00-1.08%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -20.60% | 28.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -20.60% | 28.99% | |||
| Cost of Revenue | -5.65% | 7.19% | |||
| Gross Profit | -34.97% | 60.36% | |||
| SG&A Expenses | -53.69% | 207.65% | |||
| Depreciation & Amortization | -0.59% | -4.66% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.45% | 31.62% | |||
| Operating Income | -31.76% | 22.42% | |||
| Income Before Tax | -63.00% | 0.10% | |||
| Income Tax Expenses | -24.54% | 6.85% | |||
| Earnings from Continuing Operations | -67.98% | -0.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -67.98% | -0.71% | |||
| EBIT | -31.76% | 22.42% | |||
| EBITDA | -30.75% | 21.30% | |||
| EPS Basic | -67.84% | -1.16% | |||
| Normalized Basic EPS | -64.29% | 4.13% | |||
| EPS Diluted | -47.47% | 67.80% | |||
| Normalized Diluted EPS | -62.28% | 0.00% | |||
| Average Basic Shares Outstanding | 0.04% | 0.25% | |||
| Average Diluted Shares Outstanding | -5.06% | 4.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||